TheBioTechReview

Industry Radar

Exploring the latest in Industry Radar.

The 2026 Biotech Crossroads: AI, Gene Editing, and the New Manufacturing Imperative
Industry Radar

The 2026 Biotech Crossroads: AI, Gene Editing, and the New Manufacturing Imperative

Regeneron’s Hearing Loss Gene Therapy: FDA Approval and the Hidden Value of Priority Review Vouchers
Industry Radar

Regeneron’s Hearing Loss Gene Therapy: FDA Approval and the Hidden Value of Priority Review Vouchers

Navigating the Unsayable: How Information Architecture Handles Content Rejection in Automated Systems
Industry Radar

Navigating the Unsayable: How Information Architecture Handles Content Rejection in Automated Systems

Tolebrutinib's Regulatory Crossroads: Why Europe and the FDA See Multiple Sclerosis Differently
Industry Radar

Tolebrutinib's Regulatory Crossroads: Why Europe and the FDA See Multiple Sclerosis Differently

Beyond the Hype: How AI Scientists Are Reshaping the Economics of Drug R&D
Industry Radar

Beyond the Hype: How AI Scientists Are Reshaping the Economics of Drug R&D

How AI Partnerships and Clinical Data Are Reshaping the Pharma Landscape: Merck, Google, and Roche Take Center Stage
Industry Radar

How AI Partnerships and Clinical Data Are Reshaping the Pharma Landscape: Merck, Google, and Roche Take Center Stage